Alumis
PublicAlumis is now publicly traded
The data on this page reflects Alumis's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 27, 2024
Last Round
M&A
May 21, 2025
Total Funding Raised
$779M
Company Overview
Alumis (NAS: ALMS) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for autoimmune disorders through advanced precision data analytics and expert insights.
Sector
Biotech
AI Layer
Non-AI
Keywords
Alumis Comparables
Compare Alumis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 杭州高光制药股份有限公司 | 74% | |
| Lynk Pharmaceuticals | 73% | |
| LAPIX Therapeutics | 56% |
Alumis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | May 21, 2025 | ||||
| IPO | Jun 27, 2024 | ||||
| Series C | Mar 6, 2024 | ||||
| Series B | Jan 6, 2022 | ||||
| Series A | May 5, 2021 |
Alumis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series C |
| Guggenheim Securities | IPO |
| Ally Bridge Group | Series C |
| Heartland Healthcare Capital | Series C |
| Cormorant Capital | Series C |
| Morgan Stanley | IPO |
| Foresite Capital | Series B, Series A, Series C |
Alumis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access